182 related articles for article (PubMed ID: 7686594)
1. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery.
Huang H; Ding W; Su Z; Zhang W
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):11-8. PubMed ID: 7686594
[TBL] [Abstract][Full Text] [Related]
2. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.
van Oeveren W; Harder MP; Roozendaal KJ; Eijsman L; Wildevuur CR
J Thorac Cardiovasc Surg; 1990 May; 99(5):788-96; discussion 796-7. PubMed ID: 1691806
[TBL] [Abstract][Full Text] [Related]
3. Protection of single-chain urokinase-type plasminogen activator (scu-PA) in aprotinin treated cardiac surgical patients undergoing cardiopulmonary bypass.
Spannagl M; Dooijewaard G; Dietrich W; Kluft C
Thromb Haemost; 1995 May; 73(5):825-8. PubMed ID: 7482410
[TBL] [Abstract][Full Text] [Related]
4. Tissue-type plasminogen activator and fibrin monomers synergistically cause platelet dysfunction during retransfusion of shed blood after cardiopulmonary bypass.
de Haan J; Schönberger J; Haan J; van Oeveren W; Eijgelaar A
J Thorac Cardiovasc Surg; 1993 Dec; 106(6):1017-23. PubMed ID: 8246533
[TBL] [Abstract][Full Text] [Related]
5. Hemostasis in patients undergoing extracorporeal circulation: the effect of aprotinin (Trasylol).
Lu H; Soria C; Commin PL; Soria J; Piwnica A; Schumann F; Regnier O; Legrand Y; Caen JP
Thromb Haemost; 1991 Dec; 66(6):633-7. PubMed ID: 1724577
[TBL] [Abstract][Full Text] [Related]
6. Decreased platelet number and function and increased fibrinolysis contribute to postoperative bleeding in cardiopulmonary bypass patients.
Holloway DS; Summaria L; Sandesara J; Vagher JP; Alexander JC; Caprini JA
Thromb Haemost; 1988 Feb; 59(1):62-7. PubMed ID: 2452492
[TBL] [Abstract][Full Text] [Related]
7. Aprotinin prevents cardiopulmonary bypass-induced platelet dysfunction. A scanning electron microscope study.
Mohr R; Goor DA; Lusky A; Lavee J
Circulation; 1992 Nov; 86(5 Suppl):II405-9. PubMed ID: 1385010
[TBL] [Abstract][Full Text] [Related]
8. Platelets and soluble fibrin promote plasminogen activation causing downregulation of platelet glycoprotein Ib/IX complexes: protection by aprotinin.
de Haan J; van Oeveren W
Thromb Res; 1998 Nov; 92(4):171-9. PubMed ID: 9840026
[TBL] [Abstract][Full Text] [Related]
9. Platelet function during cardiopulmonary bypass not changed by two different doses of aprotinin.
Santamaría A; Mateo J; Muñíz-Díaz E; Oliver A; Murillo J; Litvan H; Souto JC; Fontcuberta J
Haematologica; 2000 Apr; 85(4):381-5. PubMed ID: 10756363
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two aprotinin dosage regimens in pediatric patients having cardiac operations. Influence on platelet function and blood loss.
Boldt J; Knothe C; Zickmann B; Wege N; Dapper F; Hempelmann G
J Thorac Cardiovasc Surg; 1993 Apr; 105(4):705-11. PubMed ID: 7682266
[TBL] [Abstract][Full Text] [Related]
11. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
Wachtfogel YT; Kucich U; Hack CE; Gluszko P; Niewiarowski S; Colman RW; Edmunds LH
J Thorac Cardiovasc Surg; 1993 Jul; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
[TBL] [Abstract][Full Text] [Related]
12. Platelet composition and function in patients undergoing cardiopulmonary bypass for heart surgery.
Bertolino G; Locatelli A; Noris P; Maurelli M; Ceriana P; Mazzini G; Spedini P; Belletti S; Balduini CL
Haematologica; 1996; 81(2):116-20. PubMed ID: 8641638
[TBL] [Abstract][Full Text] [Related]
13. Aprotinin has no effect on platelet activation and adhesion during cardiopulmonary bypass.
Wahba A; Black G; Koksch M; Rothe G; Preuner J; Schmitz G; Birnbaum DE
Thromb Haemost; 1996 May; 75(5):844-8. PubMed ID: 8725734
[TBL] [Abstract][Full Text] [Related]
14. Aprotinin reduces blood loss after cardiopulmonary bypass by direct inhibition of plasmin.
Ray MJ; Marsh NA
Thromb Haemost; 1997 Sep; 78(3):1021-6. PubMed ID: 9308747
[TBL] [Abstract][Full Text] [Related]
15. Macroaggregation of platelets in plasma, as distinct from microaggregation in whole blood (and plasma), as determined using optical aggregometry and platelet counting respectively, is specifically impaired following cardiopulmonary bypass in man.
Menys VC; Belcher PR; Noble MI; Evans RD; Drossos GE; Pillai R; Westaby S
Thromb Haemost; 1994 Oct; 72(4):511-8. PubMed ID: 7533335
[TBL] [Abstract][Full Text] [Related]
16. Effects of nafamostat mesilate and minimal-dose aprotinin on blood-foreign surface interactions in cardiopulmonary bypass.
Kaminishi Y; Hiramatsu Y; Watanabe Y; Yoshimura Y; Sakakibara Y
Ann Thorac Surg; 2004 Feb; 77(2):644-50. PubMed ID: 14759453
[TBL] [Abstract][Full Text] [Related]
17. Low doses of aprotinin in aortocoronary bypass surgery--advantages and disadvantages.
Golański R; Golański J; Chizyński K; Iwaszkiewicz A; Zasłonka J; Pietrucha T; Chrul S; Watała C
Med Sci Monit; 2000; 6(4):722-8. PubMed ID: 11208399
[TBL] [Abstract][Full Text] [Related]
18. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass.
Kawasuji M; Ueyama K; Sakakibara N; Tedoriya T; Matsunaga Y; Misaki T; Watanabe Y
Ann Thorac Surg; 1993 May; 55(5):1205-9. PubMed ID: 7684219
[TBL] [Abstract][Full Text] [Related]
19. Combined administration of nitric oxide gas and iloprost during cardiopulmonary bypass reduces platelet dysfunction: a pilot clinical study.
Chung A; Wildhirt SM; Wang S; Koshal A; Radomski MW
J Thorac Cardiovasc Surg; 2005 Apr; 129(4):782-90. PubMed ID: 15821644
[TBL] [Abstract][Full Text] [Related]
20. Role of platelet membrane glycoproteins Ib/IX and IIb/IIIa, and of platelet alpha-granule proteins in platelet aggregation induced by human osteosarcoma cells.
Clezardin P; Drouin J; Morel-Kopp MC; Hanss M; Kehrel B; Serre CM; Kaplan C; Delmas PD
Cancer Res; 1993 Oct; 53(19):4695-700. PubMed ID: 7691402
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
